Quick Answer
DNA X, Inc. reported R&D Expense of $14.23 million for fiscal year 2024.
DNA X, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $14.23M | +703.3% |
| 2023 | $1.77M | -77.8% |
| 2022 | $7.97M | -54.9% |
| 2021 | $17.70M | +9.1% |
| 2020 | $16.22M | -37.8% |
| 2019 | $26.06M | +12.1% |
| 2018 | $23.25M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $181.0K | -74.7% | -80.1% |
| June 30, 2025 | $909.0K | +63.2% | -44.3% |
| March 31, 2025 | $1.63M | +258.1% | +128.4% |
| September 30, 2024 | $715.0K | -3.5% | +28.4% |
| June 30, 2024 | $557.0K | — | +22.1% |
| March 31, 2024 | $456.0K | +334.3% | -38.5% |
| September 30, 2023 | $741.0K | +648.9% | +605.7% |
| March 31, 2023 | $105.0K | -97.5% | +177.8% |
- DNA X, Inc. showed an increase of +703.3% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2024 period, DNA X, Inc.’s r&d expense has declined by 38.8% (from $23.25 million to $14.23 million).
- The most recent figure is from DNA X, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: